Fig. 1From: Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort studyFlow chart of the preSINO trial. nCRT: neoadjuvant chemoradiotherapy; CRE-1: first clinical response evaluation, four to six weeks after completion of nCRT; CRE-2: second clinical response evaluation, 10–12 weeks after completion of nCRTBack to article page